CalciMedica, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of CalciMedica, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst its own history
CalciMedica, Inc.'s multiples at each month end with a market cap on file, Jan 2021 to Oct 2026, each against its own median.
Price to book
1.0×Now below its median of 3.0×, in the bottom quarter of its range; range 0.4× to 6.0× over 16 months.
As of Oct 30, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | — | $-30 M | $-21 M | $0 M | $-21 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | — | $-14 M | $-21 M | $0 M | $-21 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | — | $-34 M | $-26 M | $0 M | $-26 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | — | $-8 M | $-12 M | $0 M | $-12 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | — | $-36 M | $-32 M | $0 M | $-32 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | — | $-28 M | $-32 M | $1 M | $-33 M | — | SEC annual report (10-K, 20-F) |